Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2015Expert Review of Gastroenterology & HepatologyOpen Access

Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

JJJørgen JahnsenUniversity of OsloTDTrond Espen DetlieAkershus University HospitalSVSimen VatnInnlandet Hospital Trust

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jahnsen et al. (2015) studied this question.

synapsesocial.com/papers/6a83b1cdac97fff8746a8fb2https://doi.org/10.1586/17474124.2015.1091308
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Infliximab Maintenance Therapy for Fistulizing Crohn's Disease2004 · 2,236 citations
  2. 2Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up2007 · 53 citations
  3. 3A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease1997 · 3,169 citations